Glycosylated humanized B-cell specific antibodies
US6254868A · kind A · utility
126Cited by
5References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 17, 1998 |
| Grant date | Jul 3, 2001 |
| Priority date | — |
| Expiry date | Nov 17, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A humanized specific monoclonal antibody or antibody fragment, especially a B-cell specific antibody or antibody fragment, is engineered to contain a glyxosylation site in the non-Fc constant region. The glycosylated antibody is useful for diagnosis and/or therapy whenever a targeting antibody or fragment is used, especially for B-cell malignancies. The carbohydrate moiety allows conjugation of labeling or therapeutic agents of increased size, without affecting the binding affinity or specificity of the antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.